Partial
Partially Aligned
Patient Risk:
Medium
Summary
Several interaction and muscle/liver safety statements in the AI claims appear consistent with the provided LIPITOR label excerpts (7.2, 7.4, 5.1, 5.2, 17). However, the full label context needed to verify all key items (notably boxed warnings, contraindications section wording, and dosing/administration guidance) is not provided, and multiple AI interaction claims (garlic, ginkgo, vitamin E, red yeast rice) are not supported by the supplied label text.
Category Scores
Accurate Statements
Excessive grapefruit juice consumption (>1.2 liters/day) can increase plasma concentrations of atorvastatin.
7.2 Grapefruit Juice (components inhibit CYP 3A4 and can increase plasma concentrations; especially with excessive consumption >1.2 liters/day).
Concomitant use with fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors increases the risk of myopathy during statin treatment.
7 DRUG INTERACTIONS (risk of myopathy increased with those concurrent agents) and Warnings/Precautions 5.1 (increased risk with cyclosporine, fibric acid derivatives, niacin, strong CYP3A4 inhibitors).
Concomitant use with CYP 3A4 inducers (e.g., rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
7.4 Rifamprin or other Induceder of Cytochrome P450 3A4 (variable reductions in plasma concentrations with inducers such as efavirenz, rifampin).
Rifampin is recommended for simultaneous co-administration with LIPITOR; delayed administration after rifampin has been associated with significant reduction in atorvastatin plasma concentrations.
7.4 Rifamprin or other Induceder of Cytochrome P450 3A4 (simultaneous co-administration recommended; delayed administration associated with significant reduction).
Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with LIPITOR and other drugs in this class.
5.1 Skeletal Muscle (rare cases statement).
Unsupported Statements
Red yeast rice can interact with Lipitor and increase the risk of muscle damage.
The provided label excerpts do not mention red yeast rice.
Garlic supplements can increase the risk of bleeding when taken with Lipitor.
The provided label excerpts do not mention garlic or bleeding risk related to garlic supplements.
Ginkgo biloba can increase the risk of bleeding when taken with Lipitor.
The provided label excerpts do not mention ginkgo biloba or bleeding risk related to it.
Vitamin E can increase the risk of bleeding when taken with Lipitor.
The provided label excerpts do not mention vitamin E or bleeding risk related to vitamin E.
Some supplements may decrease the levels of Lipitor in the body, affecting its metabolism and/or effectiveness.
The provided label excerpts discuss grapefruit juice and CYP3A4 inducers (e.g., rifampin) but do not provide support for a general statement about 'some supplements' broadly decreasing levels.
Lipitor interactions can lead to increased or decreased levels of the medication in the body, which can result in adverse effects or reduced efficacy.
The label excerpt supports increased plasma concentrations with grapefruit juice and variable reductions with CYP3A4 inducers, but it is not shown in the provided text that 'reduced efficacy' is specifically the result wording for these interactions.
It is essential to inform a doctor about any supplements being taken because they can interact with Lipitor and affect its effectiveness.
The provided label excerpts support informing healthcare professionals that they are taking LIPITOR, and advising about substances not to take concomitantly; they do not specifically state 'any supplements' are essential or specifically 'affect its effectiveness' in the cited text.
Lipitor is not recommended to be taken with red yeast rice.
The provided label excerpts do not mention red yeast rice or a recommendation against it.
Lipitor is not recommended to be taken with St. John's Wort.
The provided label excerpts mention CYP3A4 inducers (examples include efavirenz, rifampin) but do not mention St. John's Wort.
Contradictions
Low
AI Statement
Lipitor is not recommended to be taken with grapefruit juice.
Label Reference
7.2 Grapefruit Juice (increases plasma concentrations with excessive grapefruit juice consumption; no 'not recommended' directive is shown in the provided excerpt).
Low
AI Statement
Lipitor is not recommended to be taken with grapefruit juice.
Label Reference
7.2 Grapefruit Juice (language provided describes increased plasma concentrations, especially with >1.2 liters/day, rather than an explicit 'not recommended' prohibition).
Important Omissions
Boxed warnings (and whether any are applicable) and evaluation of all label warnings/precautions beyond skeletal muscle and liver dysfunction.
Importance:
High
Full Contraindications section verification (exact contraindications wording and whether liver disease statement belongs exactly there versus other sections).
Importance:
Moderate
Dosing and administration guidance (including any dose limits/adjustments with interacting drugs) as covered in label sections beyond the provided excerpts.
Importance:
High
Use in specific populations (e.g., pregnancy, pediatric) and associated label restrictions, since no such content was evaluated from the label excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Some claims are supported (grapefruit juice threshold, CYP3A4 inducer interaction, myopathy/rhabdomyolysis risk, withholding/discontinuation concept). However, multiple supplement-specific interaction and bleeding-risk claims are unsupported by the provided label excerpts, and at least one claim presents a stronger directive ('not recommended') than the shown labeling language for grapefruit juice.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several listed supplement interaction claims (red yeast rice, garlic, ginkgo, vitamin E, St. John's Wort) are not supported by the supplied FDA label excerpts, and grapefruit juice is framed as 'not recommended' without explicit support in the provided text.
Suggested Improvement
Limit interaction claims to those explicitly supported by the supplied label text (e.g., grapefruit juice with stated >1.2 L/day; specific CYP3A4 inhibitor/inducer classes and examples). Remove or qualify supplement-specific claims not present in the provided label excerpts, and use label-accurate phrasing (avoid 'not recommended' unless the label explicitly states it).